Condition: Non-hodgkin Lymphoma · Hodgkin Lymphoma · Sponsor: New York Medical College
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
This description comes directly from the study's public registry record.
Mitchell Cairo, MD · 9145942150 · mitchell_cairo@nymc.edu
Lauren Harrison, RN · 617-285-7844 · lauren_harrison@nymc.edu
Always discuss trial participation with your own doctor first.
| University of Alabama | Birmingham, Alabama, United States | Not Yet Recruiting |
| University of Flordia | Gainsville, Florida, United States | Recruiting |
| New York Medical College | Vallhala, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05253495